Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Regulatory News, In Brief

Executive Summary

CDC panel recommends combined regimen of Pfizer’s Prevnar 13 and Merck’s Pneumovax 23 in immunocompromised adults; FDA issues “complete response” letters and completes review of compounded hydroxyprogesterone.


Related Content

Prevnar 13 Recommendation For Medicare Population May Be Short Lived
Bankrupt KV Pharma’s Hopes For Makena Rest With Skeptical Judge
FDA’s Nonenforcement Actions Are Not Reviewable, Agency Argues In KV’s Makena Suit
Makena’s Orphan Exclusivity Is “Nullified” By FDA’s Compounding Policy, KV Suit Says
EMA Orphan Approval Path Seems More Twisty After Pfizer/Protalix’s Elelyso Stumbles
ATLAS Trial Design Blamed For Missing Data On Xarelto ACS Use
Pfizer’s Vyndaqel Splits Advisory Committee; Now It Must Move FDA
FDA Actions, In Brief
Prevnar 13 Post-Market Trials Must Confirm Surrogate Endpoint, Deal With Immunogenicity
K-V Gets FDA To Test Adequacy Of Makena’s Competing Compounded Products


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts